BioNexus Gene Lab Corp (BGLC) Balance Sheet
BGLC balance sheet, 2025
December 31, 2025 · U.S. dollars$9.3M assets = $637,856 liabilities + $8.6M equity
Both columns are drawn to the same scale: what BGLC owns equals what it owes plus shareholders’ equity. Hover a block for its value.
BGLC financial health
Descriptive bands, not a rating. Fiscal 2025.
BGLC balance sheet trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $262016 | $9.3M2025 | +313.8%/yr | |
| Total liabilities | $1,3372016 | $637,8562025 | +98.4%/yr | |
| Shareholders’ equity | −$1,3112016 | $8.6M2025 | — | |
| Cash & short-term investments | $262016 | $2.4M2025 | +255.9%/yr | |
| Total debt | $82,0632018 | $176,0462025 | +11.5%/yr | |
| Net cash (debt) | $1.2M2018 | $2.2M2025 | +$1.0M | |
| Working capital | −$1,3112016 | $4.9M2025 | +$4.9M | |
| Book value per share | −$0.002016 | $4.642025 | — | |
| Debt / equity | 0.052018 | 0.022025 | −0.03 | |
| Shares outstanding | 622K2016 | 1.9M2025 | +12.9%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
BGLC assets
BGLC liabilities and equity
BGLC debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
BGLC balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & short-term investments | $2.4M | $4.4M | $5.9M | $2.1M | $2.1M | $2.8M | $859,076 | $1.3M | $839,145 | $26 |
| Cash & equivalents | $2.4M | $4.4M | $5.9M | $2.1M | $2.1M | $2.8M | $859,076 | $659,235 | $839,145 | $26 |
| Short-term investments | $1.7M | $2.8M | $3.3M | $1.5M | $1.5M | $2.1M | $493,038 | $601,004 | $2,547 | — |
| Receivables | $648,997 | $1.6M | $857,262 | $2.9M | $3.4M | $4.0M | $2,858 | $22,814 | $125,940 | $0 |
| Inventory | $676,703 | $1.4M | $1.1M | $977,807 | $1.5M | $1.2M | $7,580 | $15,301 | $32,086 | $0 |
| Other current assets | $1.7M | $84,167 | $122,431 | $25,240 | $79,517 | $22,640 | $13,057 | $0 | $2,547 | $0 |
| Total current assets | $5.4M | $7.4M | $8.0M | $6.0M | $7.1M | $8.0M | $882,571 | $1.3M | $999,718 | $26 |
| Property, plant & equipment (net) | $1.8M | $1.7M | $1.7M | $1.6M | $1.7M | $1.8M | $336,450 | $341,805 | $273,162 | $0 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $2.0M | $1.3M | $1.7M | $1.2M | $749,027 | $281,668 | $12,215 | $12,080 | $0 | $0 |
| Other non-current assets | $0 | $0 | $1 | $0 | $67,606 | $0 | $0 | $0 | $0 | $0 |
| Total assets | $9.3M | $10.4M | $11.4M | $8.7M | $9.6M | $10.1M | $1.2M | $1.7M | $1.3M | $26 |
| Liabilities | ||||||||||
| Accounts payable | $2,335 | $1.5M | $1.4M | $1.9M | $2.0M | $3.2M | — | $22,814 | $35,092 | $1,337 |
| Short-term debt | $59,147 | $50,816 | $47,831 | $16,569 | $39,507 | $45,750 | $32,137 | $19,128 | — | — |
| Deferred revenue | $8,385 | $95,879 | $23,123 | $23,123 | $107,583 | $61,313 | — | — | — | — |
| Total current liabilities | $520,957 | $2.0M | $1.6M | $2.0M | $2.3M | $3.4M | $51,574 | $62,893 | $1.2M | $1,337 |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | $176,046 | $210,557 | $133,395 | $56,775 | $76,947 | $123,419 | $89,435 | $82,063 | — | — |
| Other long-term liabilities | $116,899 | $159,741 | $111,018 | $71,072 | $65,855 | $79,541 | $57,297 | $67,420 | $4,570 | $0 |
| Total liabilities | $637,856 | $2.1M | $1.7M | $2.1M | $2.4M | $3.5M | $108,872 | $130,313 | $1.2M | $1,337 |
| Shareholders' equity | ||||||||||
| Common stock & paid-in capital | $20.2M | $17.3M | $17.2M | $10.9M | $10.8M | $10.8M | $6.5M | $6.6M | $5.2M | $1 |
| Retained earnings (deficit) | −$6.4M | −$3.4M | −$1.8M | $1.2M | $1.5M | $760,787 | −$333,311 | −$86,842 | −$113,296 | −$1,438 |
| Accumulated other comprehensive income | −$120,749 | −$555,000 | −$677,294 | −$409,062 | −$100,262 | $133,684 | −$17,103 | −$5.0M | $14,051 | $126 |
| Total shareholders' equity | $8.6M | $8.3M | $9.7M | $6.7M | $7.2M | $6.7M | $1.1M | $1.5M | $94,626 | −$1,311 |
| Key figures | ||||||||||
| Total debt | $176,046 | $210,557 | $146,594 | $56,775 | $76,947 | $123,419 | $89,435 | $82,063 | — | — |
| Net cash (debt) | $2.2M | $4.2M | $5.8M | $2.1M | $2.0M | $2.7M | $769,641 | $1.2M | — | — |
| Working capital | $4.9M | $5.5M | $6.4M | $4.0M | $4.8M | $4.6M | $830,997 | $1.2M | −$173,966 | −$1,311 |
| Tangible book value | $8.6M | $8.3M | $9.7M | $6.7M | $7.2M | $6.7M | $1.1M | $1.5M | $94,626 | −$1,311 |
| Book value per share | $4.64 | $4.67 | $5.61 | $4.63 | $5.03 | $7.77 | $1.56 | — | $0.15 | −$0.00 |
| Shares outstanding | 1.9M | 1.8M | 1.7M | 1.4M | 1.4M | 858K | 720K | — | 622K | 622K |
| Current ratio | 10.46 | 3.81 | 4.93 | 3.00 | 3.04 | 2.37 | 17.11 | 20.64 | 0.85 | 0.02 |
| Quick ratio | 5.82 | 3.05 | 4.16 | 2.50 | 2.35 | 2.01 | 16.71 | 20.40 | 0.82 | 0.02 |
| Debt / equity | 0.02 | 0.03 | 0.02 | 0.01 | 0.01 | 0.02 | 0.08 | 0.05 | — | — |
| Equity / assets | 93.1% | 79.8% | 84.7% | 76.3% | 75.0% | 65.9% | 91.2% | 92.1% | 7.4% | −5,042.3% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $3.5M | $4.0M | $4.0M | $2.9M | $3.1M | $3.6M | $4.4M | $4.1M | $5.4M | $5.8M | $5.9M | $6.1M |
| Cash & equivalents | $1.2M | $4.0M | $2.4M | $2.9M | $814,179 | $3.6M | $4.4M | $4.1M | $5.4M | $5.8M | $5.9M | $6.1M |
| Short-term investments | $2.3M | $2.6M | $1.7M | $1.7M | $2.2M | — | — | $2.1M | $3.2M | $3.3M | — | $1.4M |
| Receivables | $185,654 | $141,471 | $505,885 | $1.6M | $2.0M | $1.5M | $1.4M | $1.4M | $995,003 | $889,999 | $799,674 | $904,234 |
| Inventory | $652,892 | $667,154 | $676,703 | $1.0M | $1.2M | $1.2M | $1.4M | $1.4M | $1.0M | $1.1M | $1.1M | $1.1M |
| Other current assets | $583,331 | $422,315 | $226,445 | $98,904 | $151,269 | $235,727 | $287,827 | $65,683 | $400,831 | $106,304 | $180,020 | $110,792 |
| Total current assets | $4.9M | $5.2M | $5.4M | $5.6M | $6.4M | $6.5M | $7.4M | $7.0M | $7.8M | $7.9M | $8.0M | $8.3M |
| Property, plant & equipment (net) | $1.8M | $1.8M | $1.8M | $1.8M | $1.8M | $1.7M | $1.7M | $2.0M | $1.6M | $1.6M | $1.7M | $1.6M |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $2.0M | $2.0M | $2.0M | $237,760 | $1.2M | $1.2M | $1.3M | $2.0M | $1.7M | $1.7M | $1.7M | $1.6M |
| Other non-current assets | $0 | $12.2M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1 |
| Total assets | $8.7M | $21.2M | $9.3M | $7.6M | $9.4M | $9.5M | $10.4M | $11.0M | $11.1M | $11.2M | $11.4M | $11.5M |
| Liabilities | ||||||||||||
| Accounts payable | $7,896 | $2,137 | $2,335 | $184,600 | $1.4M | $1.2M | $1.5M | $1.0M | $954,785 | $1.4M | $1.4M | $1.6M |
| Short-term debt | $63,542 | $66,021 | — | $56,803 | $55,809 | $52,173 | — | $48,214 | $53,210 | $32,508 | — | $33,897 |
| Deferred revenue | $8,351 | $8,416 | — | $11,264 | $11,348 | $21,964 | — | $22,834 | $5,937 | $7,094 | — | $8,218 |
| Total current liabilities | $812,938 | $796,470 | $520,957 | $678,023 | $1.8M | $1.6M | $2.0M | $1.4M | $1.4M | $1.7M | $1.6M | $1.6M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | $198,585 | $216,428 | $176,046 | $183,746 | $197,156 | $200,113 | $210,557 | $226,581 | $235,907 | $121,354 | $133,395 | $138,764 |
| Other long-term liabilities | $135,043 | $12.3M | $116,899 | $126,942 | $141,347 | $147,939 | $159,741 | $192,013 | $194,614 | $100,762 | $111,018 | $133,746 |
| Total liabilities | $947,981 | $13.1M | $637,856 | $804,966 | $1.9M | $1.7M | $2.1M | $1.6M | $1.6M | $1.8M | $1.7M | $1.8M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $20.2M | $20.2M | — | $17.3M | $17.3M | $17.3M | — | $17.3M | $17.2M | $17.2M | — | $17.3M |
| Retained earnings (deficit) | −$7.3M | −$7.0M | −$6.4M | −$5.4M | −$4.7M | −$4.1M | −$3.4M | −$3.1M | −$1.7M | −$1.9M | −$1.8M | −$1.8M |
| Accumulated other comprehensive income | −$127,209 | −$98,849 | — | −$112,547 | −$115,763 | −$482,841 | — | −$4.8M | −$884,739 | −$887,202 | — | −$800,595 |
| Total shareholders' equity | $7.8M | $8.1M | $8.6M | $6.8M | $7.5M | $7.8M | $8.3M | $9.4M | $9.5M | $9.3M | $9.7M | $9.7M |
| Key figures | ||||||||||||
| Total debt | $198,585 | $216,428 | — | $183,746 | $197,156 | $200,113 | — | $226,581 | $235,907 | $121,354 | — | $138,764 |
| Net cash (debt) | $3.3M | $3.7M | — | $2.7M | $2.9M | $3.4M | — | $3.9M | $5.2M | $5.7M | — | $6.0M |
| Working capital | $4.1M | $4.4M | $4.9M | $4.9M | $4.6M | $5.0M | $5.5M | $5.6M | $6.4M | $6.2M | $6.4M | $6.6M |
| Tangible book value | $7.8M | $8.1M | $8.6M | $6.8M | $7.5M | $7.8M | $8.3M | $9.4M | $9.5M | $9.3M | $9.7M | $9.7M |
| Book value per share | $3.22 | $3.35 | $3.56 | $3.79 | $4.19 | $4.33 | $4.63 | $5.23 | $5.40 | $5.29 | $5.47 | $5.78 |
| Shares outstanding | 2.4M | 2.4M | 2.4M | 1.8M | 1.8M | 1.8M | 1.8M | 1.8M | 1.8M | 1.8M | 1.8M | 1.7M |
| Current ratio | 6.08 | 6.52 | 10.46 | 8.30 | 3.63 | 4.19 | 3.81 | 4.98 | 5.60 | 4.61 | 4.93 | 5.03 |
| Quick ratio | 4.56 | 5.16 | 8.73 | 6.67 | 2.85 | 3.29 | 2.95 | 3.95 | 4.58 | 3.92 | 4.13 | 4.29 |
| Debt / equity | 0.03 | 0.03 | — | 0.03 | 0.03 | 0.03 | — | 0.02 | 0.02 | 0.01 | — | 0.01 |
| Equity / assets | 89.1% | 38.2% | 93.1% | 89.4% | 79.8% | 82.0% | 79.8% | 85.4% | 85.7% | 83.7% | 84.7% | 84.5% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed April 14, 2026); data from EODHD.
BGLC financial position
At the end of fiscal 2025 (December 31, 2025), BioNexus Gene Lab had total assets of $9.3 million (down 11.3% from a year earlier), total liabilities of $0.6 million and shareholders' equity of $8.6 million. It held $2.4 million in cash and short-term investments against $0.2 million of debt, a net cash position of $2.2 million. Its current ratio was 10.46. In the latest quarter (ended June 30, 2026) total assets were $8.7 million and equity $7.8 million.
Related: BGLC income statement, BGLC cash flow statement, BGLC key metrics. See the BGLC stock overview for the latest quote and news.
BGLC balance sheet FAQ
What are BioNexus Gene Lab's total assets?
BioNexus Gene Lab reported total assets of $9.3 million at the end of fiscal 2025 (December 31, 2025), compared with $10.4 million a year earlier.
How much debt does BioNexus Gene Lab have?
BioNexus Gene Lab had $0.2 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.02.
How much cash does BioNexus Gene Lab have?
BioNexus Gene Lab held $2.4 million in cash and short-term investments at the end of fiscal 2025; with $0.2 million of debt that is net cash of $2.2 million.
What is BioNexus Gene Lab's book value?
BioNexus Gene Lab's shareholders' equity (book value) was $8.6 million at the end of fiscal 2025, or $4.64 per share.
What is BioNexus Gene Lab's current ratio?
BioNexus Gene Lab had current assets of $5.4 million and current liabilities of $0.5 million, a current ratio of 10.46 (it can cover its short-term obligations).